title: Effects of gonadotropin-releasing hormone analog treatment on skin condition.
abstract: The skin is a target organ of estrogens. Thus, theoretically, a hypoestrogenic state induced by gonadotropin-releasing hormone analog (GnRHa) treatment may have effects on skin condition. The aim of this study was to evaluate skin condition during GnRHa treatment. Sixteen premenopausal women undergoing GnRHa treatment for 16 weeks, as a presurgical treatment for uterine leiomyomas, were studied. Measurement of serum estradiol levels and epidermal hydration, and evaluation of subjective findings on skin condition using a questionnaire, were performed every 4 weeks during the treatment period. Serum estradiol levels were significantly suppressed at 4 weeks of treatment, and remained low afterwards. Epidermal hydration measured by corneometer did not show any significant difference at any time point examined, compared with that before treatment. No particular subjective findings relating to the skin (dryness, wrinkling, roughness, pigmentation, itching, formication, reaction to cosmetics) were reported during treatment, whereas complaints about hot flushes and sweating were notable. The results of this preliminary study support the notion that GnRHa treatment for 16 weeks is unassociated with apparent changes in skin condition.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Osuga
authors.forename: T
authors.initials: T
authors.lastname: Yano
authors.forename: K
authors.initials: K
authors.lastname: Kugu
authors.forename: K
authors.initials: K
authors.lastname: Koga
authors.forename: K
authors.initials: K
authors.lastname: Fukuoka
authors.forename: H
authors.initials: H
authors.lastname: Matsumi
authors.forename: O
authors.initials: O
authors.lastname: Wada
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: O
authors.initials: O
authors.lastname: Tsutsumi
authors.forename: Y
authors.initials: Y
authors.lastname: Taketani
mesh_terms: D000328:Adult; D001834:Body Water; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000601:surgery; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D017698:Postmenopause; D011292:Premedication; D017697:Premenopause; D011446:Prospective Studies; D012867:Skin / Q000187:drug effects*; D012871:Skin Diseases / Q000139:chemically induced*; D011795:Surveys and Questionnaires; D014594:Uterine Neoplasms / Q000601:surgery
chemical_list: D004958:Estradiol; D016729:Leuprolide